Ticker
AZN
FTSE Rank
2
23
People
13
Board Members
11
Executives
- Country
- United Kingdom (UK)
- Industry
- Pharmaceuticals
- Website
- www.astrazeneca.com
Board
| Name | Long Function | Age | Appointed | Tenure | Mkt cap change | |
|---|---|---|---|---|---|---|
| Marcus Wallenberg | Non-Executive Director | 70 | 5 Apr 1999 | 27y 1m | ||
| Philip Broadley | Senior independent Non-Executive Director | 65 | 27 Apr 2017 | 9y | ||
| Nazneen Rahman | Director | N/A | 1 Jun 2017 | 8y 11m | ||
| Nazneen Rahman | Non-Executive Director (until Apr 9 2026) | N/A | 1 Jun 2017 | 8y 11m | ||
| Sheri McCoy | Non-Executive Director | 67 | 1 Oct 2017 | 8y 7m | ||
| Tony Mok | Non-Executive Director | 65 | 1 Jan 2019 | 7y 4m | ||
| Michel Demare | Chairman of the Board | 69 | 1 Sep 2019 | 6y 8m | ||
| Euan Ashley | Non-Executive Director | N/A | 1 Oct 2020 | 5y 7m | ||
| Diana Layfield | Non-Executive Director | N/A | 1 Nov 2020 | 5y 6m | ||
| Anna Manz | Non-Executive Director | 53 | 1 Sep 2023 | 2y 8m | ||
| Rene Haas | Non-Executive Director | N/A | 1 Jan 2025 | 1y 4m | ||
| Birgit Conix | Non-Executive Director | N/A | 1 Feb 2025 | 1y 3m | ||
| Karen Knudsen | Non-Executive Director | N/A | N/A | N/A | — |
Board Timeline
200020052010201520202025now | |
| Marcus Wallenberg | |
| Philip Broadley | 9 years |
| Nazneen Rahman | |
| Nazneen Rahman | |
| Sheri McCoy | |
| Tony Mok | |
| Michel Demare | |
| Euan Ashley | |
| Diana Layfield | |
| Anna Manz | |
| Rene Haas | |
| Birgit Conix | |
| Karen Knudsen |
Committee Chairs
| Name | Committee | Board Role | Appointed | Tenure |
|---|---|---|---|---|
| Philip Broadley | Audit Committee | Senior independent Non-Executive Director | 27 Apr 2017 | 9y |
| Michel Demare | Nomination & Governance Committee | Chairman of the Board | 1 Sep 2019 | 6y 8m |
| Sheri McCoy | Remuneration Committee | Non-Executive Director | 1 Oct 2017 | 8y 7m |
| Euan Ashley | Science Committee | Non-Executive Director | 1 Oct 2020 | 5y 7m |
| Nazneen Rahman | Sustainability Committee | Non-Executive Director (until Apr 9 2026) | 1 Jun 2017 | 8y 11m |
Executives
| Name | Level | Long Function |
|---|---|---|
| Pascal Soriot | CEO | Executive Director and Chief Executive Officer |
| Pam Cheng | N-1 | Executive Vice President, Global Operations, IT & Chief Sustainability Officer |
| Ruud Dobber | N-1 | Executive Vice President and President, BioPharmaceuticals Business |
| Marc Dunoyer | N-1 | Chief Executive Officer, Alexion and Chief Strategy Officer |
| Jorge Filho | N-1 | Chief of Artificial Intelligence Officer, Science Innovation |
| Susan Galbraith | N-1 | Executive Vice President, Oncology Research & Development |
| Cindy Hoots | N-1 | Chief Digital Officer and Chief Information Officer |
| Mark O'Connor | N-1 | Chief Scientist |
| Jeffrey Pott | N-1 | Chief Human Resources Officer, Chief Compliance Officer and General Counsel |
| Iskra Reic | N-1 | Executive Vice President, International |
| Aradhana Sarin | N-1 | Executive Director and Chief Financial Officer |